Grammatical mood

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, CNS, Capsule, Woman, Tell, Medicaid, Behavior, Hope, Therapy, Breast milk, Grammatical mood, Physician, Risk, New America (organization), Patient, Multimedia, Insurance, Pregnancy, CIV, Theft, Medical research, Benzodiazepine, Vitamin, Diagnosis, BIIB, PPD, Mental health, Central nervous system, Alertness, Confusion, Walking, Somnolence, OBGYN, Dizziness, Pharmacy, Dietary supplement, Pharmaceutical industry, Nursing, Birth control, Liquor, Gasoline, Health insurance, Hospital, Sage, Biogen

View the full release here: https://www.businesswire.com/news/home/20231213368658/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213368658/en/
    “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

Alto Neuroscience Announces Data from Presentations at the 62nd Annual Meeting of the American College of Neuropsychopharmacology

Retrieved on: 
Thursday, December 7, 2023
Mental Health, Technology, Neurology, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Artificial Intelligence, Brain, Schizophrenia, Depression, Electroencephalography, Safety, Deficit spending, Dean (education), Grammatical mood, PD, Clinical trial, Data, Patient, American College, American College of Neuropsychopharmacology, Cross, DSM-IV codes, MADRS, Cognition, Cyclothymia, MD, Harvard Medical School, Translational research, Massachusetts General Hospital, ERP, Neuroscience, EEG, Mental health, Biomarker, MDD, Medical imaging, Phosphorus, Medical device, Pharmaceutical industry, Alto

Alto Neuroscience, Inc. today announced details from three presentations on clinical development programs presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP) that took place in Tampa, Florida, from December 3-6, 2023.

Key Points: 
  • Alto Neuroscience, Inc. today announced details from three presentations on clinical development programs presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP) that took place in Tampa, Florida, from December 3-6, 2023.
  • Alto’s data demonstrate advancements in biomarker identification for precision psychiatry and the potential to improve upon the trial-and-error approach to mental health treatment.
  • The company’s AI-enabled Precision Psychiatry Platform™ is designed to predict clinical response and match each patient to the right Alto product candidate through identifying, and prospectively replicating, brain biomarkers by analyzing data generated from EEG activity, neurocognitive task performance, wearable devices, and other measures.
  • Additionally, Alto is advancing ALTO-101 into a Phase 2 proof of concept study in patients with cognitive impairment associated with schizophrenia, with topline data expected in 2025.

Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300 in Major Depressive Disorder

Retrieved on: 
Monday, December 4, 2023
Research, Mental Health, Neurology, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Major depressive disorder, Brain, Depression, Safety, Grammatical mood, Clinical trial, Data, Patient, Medicine, American College, Neuroscience, MADRS, EEG, Biomarker, Alto, MDD, Medical device, Medical imaging

Alto Neuroscience, Inc. today announced positive results from its Phase 2a study of ALTO-300 at the 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), demonstrating clinically meaningful improvements and favorable safety and tolerability in patients with major depressive disorder (MDD).

Key Points: 
  • Alto Neuroscience, Inc. today announced positive results from its Phase 2a study of ALTO-300 at the 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), demonstrating clinically meaningful improvements and favorable safety and tolerability in patients with major depressive disorder (MDD).
  • The company has initiated a Phase 2b study evaluating ALTO-300 in 200 patients with MDD, which is expected to read out in the first half of 2025.
  • Topline results from the ALTO-300 Phase 2a study include:
    A reproducible, readily scalable, and easily administered machine learning-derived EEG biomarker was identified.
  • Alto is leveraging this biomarker and prospective patient identification with EEG in its ongoing Phase 2b trial of ALTO-300.

ArrivoBio Raises $45M in Series B Financing to Advance Pipeline

Retrieved on: 
Wednesday, November 29, 2023
Mental Health, Health, General Health, Clinical Trials, Research, Science, Biotechnology, DNA, DSM-IV codes, Grammatical mood, Patient, Pelvic floor dysfunction, Male, Metabolism, FDA, Fat necrosis, Gene expression, Series, Acute pancreatitis, DNA repair, SIRT6, Death, Pancreatitis, Female, MDD, Pharmaceutical industry, Arrivo

Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.

Key Points: 
  • Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.
  • “We are extremely grateful to our investors who continue to believe in our team and our promising pipeline,” said Steve Butts, CEO of Arrivo.
  • Orlando Health Ventures led the Series B financing with additional investment from Solas BioVentures Emerging Healthcare Fund, L.P., Rex Health Ventures and several private investors.
  • “Oversubscribed capital fundraising is rare in today’s market, and today’s Series B closing is a testament to the strong data behind both pipeline treatments, SP-624 and RABI-767, which have the potential to change millions of patients’ lives.”

Most Americans View Conspiracy Theories as Dangerous, Despite Nearly 50% Believing Alien Visits Were Covered Up by the Government

Retrieved on: 
Monday, November 20, 2023
Media, Social Media, Professional Services, Thought Leadership, White House, Federal Government, Technology, Public Policy, Artificial Intelligence, COVID-19, Communications, Health, Government, School, Marxist schools of thought, Fox News, Gerald McRaney, Research, Organization, Hope, The New York Times, CNN, Snopes, Fraud, Artificial intelligence, Vaccine, Fear, Friends, University of Cambridge, Social media, Critical, Grammatical mood, ChatGPT, Mask, AI, News, Management

However, around half of respondents also believe in debunked conspiracy theories, such as that the 2020 U.S. federal election was stolen due to widespread fraud (49.8%).

Key Points: 
  • However, around half of respondents also believe in debunked conspiracy theories, such as that the 2020 U.S. federal election was stolen due to widespread fraud (49.8%).
  • Ninety percent report encountering information in the media or online that they suspected may be false or misleading.
  • Conspiracy theories spark concerns among Americans: The survey highlights the top conspiracy theories Americans believe in, with close to 50% of Americans believing aliens have visited Earth and governments are covering it up.
  • However, the bulk of Americans also agree (78%) that conspiracy theories have a detrimental effect on society, with more than two-thirds of Americans concerned about their spread.

Ontrak Announces 2023 Third Quarter Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Technology, Mental Health, Health Technology, Telemedicine, Virtual Medicine, Software, Managed Care, Health, General Health, Artificial Intelligence, Well, EBITDA, Medicaid, Interim, Grammatical mood, Fourth, PHQ-9, Acceleration, Constitutional right, EDI, OTRK, CUSIP, GAD-7, Anxiety, Qualification, Medical device, Video game, Reinsurance, Pharmaceutical industry, Security (finance)

Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the third quarter ended September 30, 2023.
  • Revenue for the third quarter of 2023 was $3.7 million, representing a 31% increase compared to the same period in 2022.
  • Operating loss for the third quarter of 2023 was $(4.1) million compared to an operating loss of $(11.1) million for the same period in 2022.
  • Adjusted EBITDA for the third quarter of 2023 was $(2.6) million compared to adjusted EBITDA of $(7.7) million for the same period in 2022.

Novel Brain Stimulation Technique Shows Promise in Patients with Hard-to-Treat Depression

Retrieved on: 
Wednesday, November 29, 2023
World Health Organization, TMS, Brain, Research, Depression, DSM-IV codes, Post-traumatic stress disorder, Grammatical mood, Psychotherapy, Patient, Transcranial magnetic stimulation, FDA, Brain Stimulation (journal), Weight gain, Anxiety, PTSD, Disability, Life, Pharmaceutical industry, Nursing

DENVER, Nov. 29, 2023 /PRNewswire/ -- By making slight modifications to an already approved brain stimulation technique called transcranial magnetic stimulation (TMS), researchers have reported profound improvement in patients with hard-to-treat depression. Overall, 66% of patients with major depressive disorder who took part in the study responded to the novel treatment, and 42% showed acute remission. This is significantly higher than the 29% response rate reported for the standard FDA-approved protocol and also better than the response rates reported for alternative evidence-based protocols. 

Key Points: 
  • Two-thirds of patients positively responded to TMS treatment, and nearly half showed acute remission
    DENVER, Nov. 29, 2023 /PRNewswire/ -- By making slight modifications to an already approved brain stimulation technique called transcranial magnetic stimulation (TMS), researchers have reported profound improvement in patients with hard-to-treat depression.
  • Overall, 66% of patients with major depressive disorder who took part in the study responded to the novel treatment, and 42% showed acute remission.
  • Only 30-50% of patients experience full recovery or remission when treated with psychotherapy or medication.
  • During the trial, more than three dozen patients underwent TMS to a region in the front left portion of the brain.

A man who lives a relentlessly drab life finds himself at the center of a whirlwind of profound vision and insight in new book

Retrieved on: 
Wednesday, November 22, 2023
Beauty, Hay House, Love, Mysticism, Transformation, Humour, Avenue, Life, Grammatical mood, Book

AKRON, Ohio, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Dale DeLong marks his debut in the publishing scene with the release of "Tearing Up the Avenue: A Book of Transformation" (published by Balboa Press).

Key Points: 
  • Each of their stories is a gripping account of spiritual, emotional and psychological transformation that also asks readers "Why do we find ourselves here?"
  • "Tearing Up the Avenue" is a novel about loss and the experience of terrible abuse, but also a book about love, prophecy, and mysticism.
  • I want them to know there are ways we can heal and grow, regardless of what we have encountered.
  • There is beauty, wonder, and levity in all environments, as well as challenges that are often difficult to fathom."

CompassCare Receives Generous Support to Expand Ethical Medical Care in New York

Retrieved on: 
Monday, November 20, 2023
Woman, Pregnancy, Face, String interpolation, Legislation, Grammatical mood, Heart, Birth control

ROCHESTER, N.Y., Nov. 20, 2023 /PRNewswire-PRWeb/ -- CompassCare, a New York-based pro-life Medical Network, is delighted to announce a significant milestone in its mission to provide ethical medical care and comprehensive support to women facing unplanned pregnancies. Despite facing challenges, including a regrettable incident last year, CompassCare remains dedicated to supporting women and babies, emphasizing compassion and choice.

Key Points: 
  • ROCHESTER, N.Y., Nov. 20, 2023 /PRNewswire-PRWeb/ -- CompassCare, a New York-based pro-life Medical Network, is delighted to announce a significant milestone in its mission to provide ethical medical care and comprehensive support to women facing unplanned pregnancies.
  • New York City is known for its high abortion rates, and CompassCare aims to make a positive impact by offering alternatives and support for women.
  • New York seeks to imprison women facing unplanned pregnancy in hopelessness, robbing them of the support needed to enable true choice, support that only pro-life pregnancy centers provide, for free."
  • CompassCare remains committed to its mission of providing ethical medical care and support to empower women to make choices that align with their values.

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
Research, MADRS, Ageing, MDD, DBP, DSM-IV codes, Icahn School of Medicine at Mount Sinai, Neurocrine, Neurocrine Biosciences, JAMA Neurology, OLE, MPC, Mount Sinai, SCN8A, Webcast, Seizure, FOS, Safety, Epilepsy, Generalized tonic–clonic seizure, Patient, Grammatical mood, Pharmaceutical industry, Cryptocurrency, Xenon

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Xenon anticipates that patient enrollment in X-TOLE2 will be completed in the second half of 2024.
  • Other income for the quarter ended September 30, 2023 was $7.1 million, compared to $0.4 million for the same period in 2022.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its third quarter 2023 results.